Pfizer Bivalent COVID-19 Vaccines

	Pfizer Bivalent (BA.4-5) 12 years+	Pfizer Bivalent (BA.1) 18 years+
Targeted variants	Omicron BA.4-5 and Original	Omicron BA.1 and Original
Approved age	12 years and older	18 years and older
Primary dose	Yes	Yes
Booster dose	Yes, for individuals aged 12 years and older who are recommended to receive a COVID-19 booster according to the latest ATAGI advice - February 2023 advice/September 2023 advice	Yes, for individuals aged 18 years and older who are recommended to receive a COVID-19 booster according to the latest ATAGI advice - February 2023 advice/September 2023 advice
Dose volume	0.3mL	0.3mL
Doses per vial	6	6
Dilution required	No	No
Refrigerated storage time	70 days within the 24-month shelf life	70 days within the 24-month shelf life
Vial and carton	MRNATY"injection inallomicron BA.4: Original/Omicron BA.4: Original/Omicron BA.4-5 from 12 years original/Omicron BA.4-5 from 12 years original/Omicron BA.4: Original/Omicron BA.4-5 from 12 years original/Omicron BA.4-5 from 12 years original/Omicron BA.4-5 from 12 years original/Omicron in 15/15 micrograms per dose (CVIV)-19 mRNA Vaccine (nucleoside modified) One dose contains 15 micrograms to riginameran and 15 micrograms mRNA encoding Omicron BA.4 and BA.5. Intramucular use 10 multidose vials,	COMIRNATY injection adults and adolescents dispersion for injection 15/15 micrograms/dose Covid-19 mRNA Vaccine (nucleoside modified) One dose contains 15 micrograms tozinameran and 15 micrograms ititozinameran intranuscular use, Do not dilute prior to use 10 multidose vials (Each vial contains 6 doses of 0.3 mL.)

Example thawed use-by date label

Batch: GE3042
Defrost Date: 01/12/2022
Use By Date: 09/02/2023
Store at 2°-8°C & protected from light.
DO NOT RE-FREEZE

Pfizer Bivalent (BA.1) 18 years+ (Grey)

Batch: GE3042

Defrost Date: 01/12/2022

Use By Date: 09/02/2023

Store at 2°- 8°C & protected from light.

DO NOT RE-FREEZE

Useful Resources: COVID-19 Vaccines in Australia, ATAGI recommended COVID-19 vaccine doses and ATAGI clinical guidance for COVID-19 vaccine providers

